Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroblastoma 2Small Cell Lung Carcinoma 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Colonic Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × becatecarin × Clear all
NCT00005817 2013-02-01

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡